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Abstract
Hearing loss is a highly heterogeneous disease presented with various phenotypes. Genetic testing of disease-causing mutations
plays an important role in precise diagnosis and fertility guidance of heredity hearing loss. Here we reported an effective method
employing target enrichment and BGISEQ-500 platform to detect clinically relevant alterations for heredity hearing patients in a single
assay.
In this study, we designed an array based chip, containing 127 genes related to hearing loss. Then we conducted targeted next-
generation sequencing toward 58 patients to make a precise diagnosis using BGISEQ-500 platform.
We successfully detected disease-causing mutations in 77.59% (45/58) of the patients with hearing loss. Finally, a total of 62
disease-causing mutations were identiﬁed, including 31 missense, 17 Indel, 11 splicing, 2 synonymous, and 1 copy number variant.
58.06% (36/62) of which has never been reported before.
To our knowledge, this is the ﬁrst report using BGISEQ-500 platform to investigate both syndromic and nonsyndromic hearing loss
in the Chinese population. The results showed that this method can greatly assist and enhance hearing loss diagnosis and improve
molecular diagnostics outcome.
Abbreviations: CNVs = copy number variants, DNBs = DNA NanoBalls, HL = hearing loss, NGS = next-generation sequencing,
SHI = syndromic hearing impairment.
Keywords: BGISEQ-500, hearing loss, mutation detection, targeted NGS1. Introduction
Hearing loss (HL) is a highly heterogeneous disease presenting
with various phenotypes, mainly caused by environmental or
genetic factors.[1] Large scale genetic screenings have been
reported in several studies.[2,3] Early identiﬁcation and manage-Editor: Anish Thachangattuthodi.
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1ment play a crucial role in improving the communication and
language of the patients.[4] So effective, exact and timely genetic
testing is really important.
HL is a highly heterogeneous disorder. According to the
phenotypes of HL patients, hereditary HL can be classiﬁed as
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Figure 1. Gene classiﬁcation of the HL panel. HL = hearing loss.
Sun et al. Medicine (2019) 98:12 Medicineties in other organs in nonsyndromic HL patients, which account
for 70% of cases affected by hereditary HL. Syndromic HL, on
the other hand, accounts for about 30% of the patients with
hereditary HL. The inherit patterns of HL is various, including
autosomal recessive (80%), autosomal dominant (20%),
X-linked, Y-linked, and mitochondrial.[5,6]
The most frequently mutated genes/mutations for HL patients
might be different across ethnicities. In the Chinese patients with
hereditary HL, the most commonly identiﬁed disease-causing
genes are GJB2 (21%), SLC26A4 (14.5%), and MT-RNR1
(4%).[7,8] Genetic testing has been applied in newborn and carrier
screening of hereditary HL.[9–11] Some researchers performed
Sanger sequencing in the screening of frequent mutations. Wu
et al performed genetic hearing screening in 5173 newborns from
Taiwan using 4 recurrent deafness mutations, including 2
mutations in gene GJB2 (c.235delC and p.V37I), 1 mutation
in SLC26A4 (c.919-2A>G), and on mitochondrial mutation
(m.1555A>G).[12] Hao et al screened 142,417 neonates from
Wuhan using 4 recurrent deafness mutations, including 1
mutation in gene GJB2 (c.235delC), 1 mutation in gene
SLC26A4 (c.919-2A>G), and 2 mitochondrial mutations
(m.1494C>T and m.1555A>G).[13] However, genetic hearing
screening using a small number of recurrent mutations is
insufﬁcient. To date, there are more than a 100 genes described
to be related to HL.[14–16] What is more, population-scale
screening and diagnosis of recurrent mutations using Sanger
sequencing are laborious, costly and time-consuming. To detect
recurrent mutations in large cohort, tens of thousands of
polymerase chain reaction (PCR) reactions need to be performed.
With the development of next-generation sequencing (NGS), it is
gradually starting to play an important role to sequence clinical
relevant genes in various genetic disorders. The diagnostic yield in
hereditary HL can be greatly improved compared with Sanger
sequencing.What is more, NGS technology is more suitable in the
diagnosis of diseases with high genetic heterogeneity (such as
hereditary HL).[17–20]
In this study, in order to make an accurate genetic diagnosis for
patients with HL, we developed an NGS method targeting 127
genes related to HL. We tested its performance in detecting
clinically relevant mutations using BGISEQ-500 platform. We
also applied this panel to 58 clinical HL cases, and identiﬁed
disease-causingmutations in 45 patients. This method can greatly
assist and enhance HL diagnosis and help to make a precise
diagnosis for the patients. To the best of our knowledge, this is the
ﬁrst report to investigate both syndromic and nonsyndromic HL
using BGISEQ-500 platform in the Chinese population.2. Material and methods
2.1. Design of the hereditary HL panel
In this study, we designed a custom human array spanning
620,604bp using RocheNimbleGen. The array targets exons and
10bp ﬂanking intronic sequences of a total of 127 HL related
genes, which were collected based on 4 well-known databases
(Deafness Variation Database, The Hereditary Hearing Loss
Homepage, GeneReviews, Orphanet and published papers). This
array not only contained reported genes related to nonsyndromic
HL, but can also be used to diagnose a total of 39 syndromic
hearing impairment (SHI) (data not shown). The 127 genes can
be classiﬁed into 5 categories, including 45 genes related to
autosomal recessive nonsyndromic hearing loss, 3 genes related
to X-link nonsyndromic hereditary hearing loss, 29 genes related2to autosomal dominant nonsyndromic hearing loss, 2 genes
related to maternally inherited hearing loss, and 66 genes related
to SHI (Fig. 1).
2.2. Sample collection, DNA extraction, library
construction, and sequencing
In the present study, a total of 58 suspicious and conﬁrmed HL
patients were enrolled between April 2016 and May 2018 in
Anhui Provincial Hospital, Ma’anshan Maternal and Child
Health Hospital, and Yancheng Maternity and Child Health
Care Hospital. Table 1 showed the age of the 58 patients (from 2
to 43 years old). In order to exclude HL patients due to
nongenetic reasons, (such as injury and infection) and to
characterize the severity of HL, clinical information of the
patients was summarized by experienced clinicians.[21] Written
informed consent was obtained from all the participants or their
parents before sample collection. The ethics committee of BGI
approved this study and all the protocols used in the study (BGI-
IRB15083).
To the best of our knowledge, this is the ﬁrst report to
investigate both syndromic and nonsyndromic HL using
BGISEQ-500 platform in the Chinese population. Figure 2
shows the procedures of library construction and sequencing
using the BGISEQ-500 platform. First, genomic DNA of all the
participants was isolated by QIAamp DNA Blood Midi Kit
(Qiagen, Hilden, Germany). Library preparation was conducted
at BGI following the guide of the standard protocol. Library
preparation (BGISEQ-500RS High-throughput sequencing kit,
PE50, V3.0, MGI Tech Co, Ltd, Shenzhen, China), hybridization
and sequencing were performed according to the manufacturer’s
standard procedure provided by BGI (BGI-Shenzhen). In brief,
enzymatic method including digestion by segmentase (MGI Tech
Co, Ltd, BGI) was performed for DNA library construction of all
the samples. Digestion reaction, end repair, and A-tailing were
performed at the same time (37°C for 20minutes, 65°C for 15
minutes, and hold at 4°C). DNA fragments were then ligated to
adapter sequence after fragment selection. The ligation products
were puriﬁed and ampliﬁed for 7 cycles with DNA fragments
between 170bp and 230bp, and then subjected to the following
hybridization process. Each library was pooled, and then
hybridized to the HL chip for 16hours at 65°C. After sequence
capture, the libraries were washed, and then eluted according to
the manufacturer’s standard procedure (MGI Tech Co, Ltd). The
Table 1
Detection results of the 58 HL patients.
Sample
name
Gender/age,
yr old Mutation
Mutation
type
Mutation
status Reference Validation
HL1 Female/31 OTOG (NM_001277269): c.1190G>A (p.Arg397Gln) Het Novel – –
HL2 Female/4 SLC26A4 (NM_000441): c.919-2A>G;
SLC26A4 (NM_000441): c.2000T>C (p.Phe667Ser);
GJB2 (NM_004004): c.235delC (p.Leu79CysfsX3)
Het;
Het;
Het
Reported;
Reported;
Reported
PMID: 12676893;
PMID: 28576516;
PMID: 21329993
–
HL3 Female/30 GJB2 (NM_004004): c.109G>A (p.Val37Ile) Hom Reported PMID: 12121355 Yes
HL4 Male/9 SLC26A4 (NM_000441): c.1544+9C>T;
SLC26A4 (NM_000441): c.1519delT (p.Leu507Ter);
WFS1 (NM_006005): c.2596G>A (p.Asp866Asn)
Het;
Het;
Het
Reported;
Novel;
Reported
PMID: 21704276;
–
PMID: 12955714
Yes
HL5 Male/7 SLC26A4 (NM_000441): c.249G>A (p.Trp83Ter);
SLC26A4 (NM_000441): c.919-2A>G
Het;
Het
Novel;
Reported
-
PMID: 18641518
Yes
HL6 Female/43 MYO15A (NM_016239): c.3026C>A (p.Pro1009His);
MYO15A (NM_016239): c.5134-10C>G
Het;
Het
Reported;
Novel
PMID: 23767834;
–
Yes
HL7 Male/5 SLC26A4 (NM_000441): c.2027T>A (p.Leu676Gln);
SLC26A4 (NM_000441): c.915_916insG (p.Ile305IlefsX25)
Het;
Het
Reported;
Reported
PMID: 24007330;
PMID: 26252218
Yes
HL8 Male/18 SLC26A4 (NM_000441): c.919-2A>G;
SLC26A4 (NM_000441): c.1519 delT (p.Leu507TerfsX5)
Het;
Het
Reported;
Novel
PMID: 12676893;
–
Yes
HL9 Male/7 PTPRQ (NM_001145026): c.5942+1G>A;
PTPRQ (NM_001145026): c.6024G>A (p.Ser2008Ser)
Het;
Het
Novel;
Novel
–
–
Yes
HL10 Male/4 GJB2 (NM_004004): c.109G>A (p.Val37Ile);
MYO15A (NM_016239): c.3026C>A (p.Pro1009His);
MYO15A (NM_016239): c.10420A>G (p.Ser3474Gly)
Het;
Het;
Het
Reported;
Reported;
Novel
PMID: 12121355;
PMID: 23767834;
–
Yes
HL11 Female/9 GJB3 (NM_024009): c.538C>T (p.Arg180Ter);
ESPN (NM_031475): c.1464+2T>A
Het;
Het
Reported;
Novel
PMID: 22154049;
–
Yes
HL12 Male/24 GJB2 (NM_004004): c.235delC (p.Leu79CysfsX3) Het Reported PMID: 21329993 Yes
HL13 Male/43 MT-RNR1 (NC_012920): 908 A>G/m.1555A>G;
MYO6 (NM_004999): c.118-2A>G
Hom;
Het
Reported;
Novel
PMID: 24092330;
–
Yes
HL14 Male/26 GJB2 (NM_004004): c.235delC (p.Leu79CysfsX3) Hom Reported PMID: 21329993 Yes
HL15 Female/20 SLC26A4 (NM_000441): c.919-2A>G;
SLC26A4 (NM_000441): c.1686_1687insA (p.Phe562PhefsX12);
GJB2 (NM_004004): c.109G>A (p.Val37Ile)
Het;
Het;
Het
Reported;
Reported;
Reported
PMID: 12676893;
PMID: 27792752;
PMID: 12121355
–
HL16 Female/12 SLC26A4 (NM_000441): c.2168A>G (p.His723Arg);
SLC26A4 (NM_000441): c.2107C>G (p.Leu703Val)
Het;
Het
Reported;
Reported
PMID: 23705809;
PMID: 26100058
Yes
HL17 Female/7 TRIOBP (NM_001039141): c.2321delG (p.Arg774HisfsX105) Het Novel – Yes
HL18 Female/29 DIAPH3 (NM_001042517): c.3431delC (p.Thr1144SerfsX17);
MYO15A (NM_016239): c.10245_10247delCTC
Het;
Hom
Novel;
Novel
–
–
Yes
HL19 Male/25 GJB2 (NM_004004): c.235delC (p.Leu79CysfsX3) Hom Reported PMID: 21329993 Yes
HL20 Male/16 MT-RNR1 (NC_012920): m.1119T>C Hom Novel – –
HL21 Female/37 SLC26A4 (NM_000441): c.1229C>T (p.Thr410Met);
TRIOBP (NM_001039141): c.3256C>A (p.Pro1086Thr)
Het;
Hom
Reported;
Novel
PMID: 21961810;
–
Yes
HL22 Female/7 DSPP (NM_014208): c.1057delA (p.Lys353AsnfsX3) Het Novel – Yes
HL23 Male/28 DIAPH1 (NM_001079812): c.1982C>T (p.Pro661Leu) Het Novel – –
HL24 Female/5 GJB2 (NM_004004): c.235delC (p.Leu79CysfsX3);
MITF (NM_198159): c.1025_1032delGGAACAAG (p.Trp342TrpfsX25)
Het;
Het
Reported;
Novel
PMID: 21329993;
–
Yes
HL25 Female/28 SLC26A4 (NM_000441): EX5_6 DEL;
SLC26A4 (NM_000441): c.1339delA (p.Lys447SerfsX8);
TMC1 (NM_138691): c.1586_1587delTC (p.Val529ValfsX2)
Het;
Het;
Het
Reported;
Novel;
Reported
PMID: 17443271;
–;
PMID: 21250555
Yes
HL26 Female/28 CDH23 (NM_022124): c.9640C>A (p.Leu3214Met);
PCDH15 (NM_033056): c.3807G>T (p.Glu1269Asp)
Het;
Het
Novel;
Novel
–
–
–
HL27 Male/7 SLC26A4 (NM_000441): c.1336C>T (p.Gln446Ter);
SLC26A4 (NM_000441): EX5_6 DEL
Het;
Het
Reported;
Reported
PMID: 17718863;
PMID: 17443271
Yes
HL28 Female/4 MYO7A (NM_000260): c.562C>G (p.Gln188Glu) Het Novel – –
HL29 Female/4 GJB2 (NM_004004): c.257C>G (p.Thr86Arg);
GJB2 (NM_004004): c.235delC (p.Leu79CysfsX3)
Het;
Het
Reported;
Reported
PMID: 21329993;
PMID: 21329993
Yes
HL30 Female/8 SLC26A4 (NM_000441): c.919-2A>G;
SLC26A4 (NM_000441): c.1149+1G>A
Het;
Het
Reported;
Reported
PMID: 12676893;
PMID: 21961810
–
HL31 Female/2 GJB2 (NM_004004): c.109G>A (p.Val37Ile);
MYO7A (NM_000260): c.1004C>G (p.Ala335Gly)
Het;
Het
Reported;
Novel
PMID: 12121355;
–
Yes
HL32 Male/2 MYO7A (NM_000260): c.586C>G (p.Leu196Val);
MYO7A (NM_000260): c.1679A>G (p.Tyr560Cys)
Het;
Het
Novel;
Novel
–
–
Yes
HL33 Male/15 SLC26A4 (NM_000441): c.919-2A>G;
OTOF (NM_194248): c.4023+1G>A;
KCNQ4 (NM_172163): c.1905G>A (p.Ser635Ser)
Het;
Het;
Het
Reported;
Reported;
Novel
PMID: 12676893;
PMID: 21935370;
–
Yes
(continued )
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Table 1
(continued).
Sample
name
Gender/age,
yr old Mutation
Mutation
type
Mutation
status Reference Validation
HL34 Male/7 SLC26A4 (NM_000441): c.919-2A>G Het Reported PMID: 12676893 Yes
HL35 Male/8 SLC26A4 (NM_000441): c.1001+5G>C;
SLC26A4 (NM_000441): c.1226G>A (p.Arg409His);
USH2A (NM_206933): c.2802T>G (p.Cys934Trp)
Het;
Het;
Het
Reported;
Reported;
Reported
PMID: 27729126;
PMID: 23273637;
PMID: 25649381
Yes
HL36 Male/7 EDN3 (NM_000114): c.142G>A (p.Glu48Lys) Het Novel – Yes
HL37 Male/3 MYO15A (NM_016239): c.9400C>T (p.Arg3134Ter);
MYO15A (NM_016239): c.10245_10247delCTC
Het;
Het
Reported;
Novel
PMID: 23208854;
–
Yes
HL38 Male/5 SLC26A4 (NM_000441): c.281C>T (p.Thr94Ile);
SLC26A4 (NM_000441): c.919-2A>G;
TRIOBP (NM_001039141): c.4429_4430insG (p.Trp1477TrpfsX25);
Het;
Het;
Het;
Reported;
Reported;
Novel;
PMID: 17718863;
PMID: 12676893;
–
Yes
HL39 Female/23 GJB2 (NM_004004): c.235delC (p.Leu79CysfsX3) Hom Reported PMID: 21329993 Yes
HL40 Female/– GJB2 (NM_004004): c.235delC (p.Leu79CysfsX3);
KCNQ1 (NM_000218): c.2016_2017insGATGAGGGGTCCT (p.Pro672ProfsX6);
TRIOBP (NM_001039141): c.3943_3944insCTCTTCGG (p.Arg1315ProfsX44);
TRIOBP (NM_001039141): c.3941A>C (p.Glu1314Ala)
Hom;
Het;
Het;
Het
Reported;
Novel;
Novel;
Novel
PMID: 21329993;
–
–
–
Yes
HL41 Female/29 MYO15A (NM_016239): c.5964+3G>A;
MYO15A (NM_016239): c.8681_8682insA (p.Ile2894IlefsX32)
Het;
Het
Reported;
Novel
PMID: 23767834;
–
Yes
HL42 Male/28 GJB2 (NM_004004): c.235delC (p.Leu79CysfsX3) Het Reported PMID: 21329993 Yes
HL43 Female/27 SLC26A4 (NM_000441): c.919-2A>G;
SLC26A4 (NM_000441): c.2168A>G (p.His723Arg);
TRIOBP (NM_001039141): c.5185-2A>G;
PTPRQ (NM_001145026): c.3194delT (p.Ile1065IlefsX6)
Het;
Het;
Het;
Het
Reported;
Reported;
Novel;
Novel
PMID: 12676893;
PMID: 23705809;
–
–
Yes
HL44 Female/6 TMC1 (NM_138691): c.2050G>C (p.Asp684His) Hom Novel – Yes
HL45 Male/12 SLC26A4 (NM_000441): c.919-2A>G Hom Reported PMID: 14508505 Yes
HL46 Female/– – – – –
HL47 Male/11 – – – –
HL48 Male/6 – – – –
HL49 Female/5 – – – –
HL50 Female/3 – – – –
HL51 Female/30 – – – –
HL52 Male/11 – – – –
HL53 Male/30 – – – –
HL54 Male/18 – – – –
HL55 Male/22 – – – –
HL56 Male/– – – – –
HL57 Female/19 – – – –
HL58 Male/10 – – – –
Sun et al. Medicine (2019) 98:12 Medicineproducts of library construction were then subjected to the
circularization process. BGISEQ-500 applied DNA NanoBalls
(DNBs) technology for sequencing library construction. The
following DNBs making, DNBs loading, and sequencing were
conducted according to BGISEQ-500 platform protocol. BGI-
SEQ-500 platform was then used to generate the raw images and
the results of base calling.
2.3. Bioinformatics analysis and reporting
In this study, we developed a new bioinformatics analysis
pipeline, including data ﬁltration, sequence alignment, variants
calling, and annotation.
First, raw sequencing reads (FASTQ ﬁles) were evaluated
using SOAPnuke to generate “clean reads” for further analysis
(removing low-quality bases, adapters, and other technical
sequences). After reads ﬁltering, we used BWA to align the 50bp
clean reads to hg19 (the human reference genome). Then, Picard4was used to sort the BAM ﬁles. To improve read mapping, we
then used GATK and Picard to perform local realignment and
removal of PCR duplicates. Next, we used GAKT to detect
sequence variants (SNVs, Indels and copy number variants
[CNVs]) as reported before.[22] Variant annotation was
performed using our own PERL scripts. In the annotation
step, we downloaded 5 well-known databases to facilitate
annotation, including HGMD, dbSNP, 1k Genome, HapMap,
dbNSFP, and a local database of our own (596 Chinese healthy
adults).
We performed the following criteria to detect candidate
variants in HL patients:1. the number of supporting reads for the variant site are more
than 10;
the percentage for the variant site is more than 20%;2.
3. a read is kept only when more than 50% sites of the read are
tested with a Phred base quality score of more than 5.
Figure 2. Flow diagram of library construction using BGISEQ-500.
Sun et al. Medicine (2019) 98:12 www.md-journal.comFor the nonreported variants, they were recognized as potential
variants using the following criteria:1. the variants were recorded in the following dataset with a
frequency of less than 5%:HapMap,NCBI dbSNP, 1K human
genome database, and our own polymorphism dataset of 596
Chinese healthy controls;
the impact of the potential variants (predicted by dbNSFP2.
(PolyPhen-2,[23] SIFT,[24] MutationTaster,[25] PhyloP[26])) is
pathogenic or likely pathogenic.
Finally, validation was carried out using methods other than
targeted NGS.2.4. Variants validation
Clinical disease-causing mutations identiﬁed using BGISEQ
platform in the patients were conﬁrmed by methods other than
targeted NGS (http://links.lww.com/MD/C895). If a pathogenic
mutation was detected, segregation analysis was also performed
for conﬁrmation when the samples were available. For the
validation among the proband family members, we performed
Sanger sequencing (ABI 3730) for SNVs and Indels, real-time5quantitative PCR (ABI StepOne) for CNVs. Regions of interest
were ampliﬁed using polymerase chain reaction.3. Results
3.1. High-throughput NGS
In this study, we developed a targeted NGS assay to detect
disease-causing alterations in 58 patients diagnosed with HL
using BGISEQ-500 platform.
A total of 58 HL patients and their family members were
recruited in this study. We obtained high-quality reads of all the
samples by BGISEQ-500 sequencer. After base calling and image
analysis using BGISEQ-500 sequencers, primary data was
received in the form of FASTQ. Then we used bioinformatics
analysis pipeline to analyze the raw sequencing data. The
sequencing results of all the patients are as follows: more than
99.12% coverage of the target region was achieved for each
sample, and average sequencing depth of 251.37-fold was
achieved for each sample. On average, 96.85% of the target
region was successfully covered by sequencing data at more than
30-folds, which indicated that this method is reliable in
identifying potential disease-causing mutations.3.2. Diagnostic yield with targeted NGS in HL patients
The development of NGS has accelerated the discovery of genes
and mutations that underlie Mendelian diseases. In this study, we
used the above mentioned pipeline to detect potential disease-
causing mutations. After the ﬁltering process, a total of 62
disease-causing mutations were identiﬁed ﬁnally, including 31
missense, 17 Indels, 11 splicing, 2 synonymous, and 1 CNV.
58.06% (36/62) of disease-causing mutations has never been
reported before (Table 1).
The diagnostic yield is highly related to clinical scientists. In
this study, all the suspected HL patients were ﬁrst evaluated by
experienced clinical scientists. Of all the 58 random HL patients,
77.59% (45/58) were found to have deleterious mutations and
have molecular conﬁrmation of the clinical diagnosis (Table 1). It
was also observed that mutations in gene SLC26A4 (35.80% of
all the disease-causing mutations), GJB2 (12.35%), and
MYO15A (11.11%) were the most frequently detected genes
in our cohort (Fig. 3).
3.3. Mutation validation
We performed Sanger sequencing (ABI 3730 DNA sequencer) to
conﬁrm the reported potential disease-causing SNVs and Indels
(Table 1). We performed real-time quantitative PCR (ABI
StepOne) to validate all the reported potential CNVs. All the
primers used in this study were designed by Primer6.0.
Cosegregation analysis was also performed to validate the
results when the samples are available. For the 36 novel
mutations, 17 of which were successfully validated and
cosegregated with the phenotype (HL) in their families.4. Discussion
In the past few years, large scale genetic screenings of HL have
been performed,[12,13] however, most of these studies only
focused on several most common variants (such as c.235delC of
GJB2, c.919-2A>G of SLC26A4, and mitochondrial
m.1555A>G). Accurate and timely detection of other disease-
Figure 3. Clinical mutations identiﬁed in the 58 clinical cases. Red rectangles indicated the proportion of novel mutations, orange rectangles indicated reported
mutations.
Sun et al. Medicine (2019) 98:12 Medicinecausingmutations and related genes play a pivotal role in patients
with HL. With the development of NGS, identiﬁcation of clinical
relevant mutations in HL patients has become an option for
clinicians. In this study, we established a targeted NGS
technology for patients with HL. We performed BGISEQ-500
PE50 sequencing to detect clinically relevant alterations in HL
patients in real clinical setting. This newly designed panel targets
a total of 127 HL related genes. We applied this panel to 58
clinical HL cases, and identiﬁed disease-causing mutations in 45
patients. This new method can greatly improve the diagnostic
yield in HL patients and help to make a precise genetic diagnosis.
To the best of our knowledge, this is the ﬁrst report to investigate
both syndromic and nonsyndromic HL using BGISEQ-500
platform in the Chinese population.
For the 58 clinical HL cases, most of the disease-causing
mutations were found in the SLC26A4 gene (35.80%), followed
by GJB2 (12.35%), MYO15A (11.11%), TRIOBP (7.41%),
MYO7A (4.94%), PTPRQ (3.70%), MT-RNR1 (2.47%), and
TMC1 (2.47%) (Fig. 3). The results showed that the SLC26A4
(NM_000441) c.919-2A>G mutation is the leading cause in this
study. It has been reported that GJB2 is the leading cause of
heredity HL in the Chinese population.[7,8,12,23] Due to the
limited number of recruited HL patients, GBJ2 was found to be
the second leading cause in this study (Fig. 3). These results
suggested that a minority of HL patients can be deﬁned using a
small number of recurrent mutations at predeﬁned positions.
NGS technology targeting multiple disease-causing genes is more
suitable for the diagnosis of hereditary HL. However, there are
still 13 patients with negative results. No disease-causing
mutations were identiﬁed in the exons of the 127 HL related
genes in these patients. The disease-causing mutations of these
cases may locate in the intron region, noncoding region, or6undiscovered genes. Other factors (multiple genetic and
nongenetic causes) may also impact the diagnostic yield.
Interestingly, we detected 2 synonymous mutations in proband
HL9 and HL33, which were recognized as the disease-causing
mutations in their families. A novel heterozygous variant
(c.6024G>A, p.Ser2008Ser) was detected in exon 37 of gene
PTPRQ in proband HL9. A novel heterozygous variant
(c.1905G>A, p.Ser635Ser) was identiﬁed in exon 13 of gene
KCNQ4 in proband HL33. These 2 synonymous mutations were
not found the 596 healthy controls, and were all validated by
Sanger sequencing. Both of these 2 synonymous mutations
cosegregated with HL in their families. Although synonymous
mutations were predicted to be benign and did not change the
sequence of amino acid, we still believe these 2 mutations were
the disease-causing mutations of HL. More than 50 diseases
afﬂicting most organ systems have been reported to be associated
with synonymous mutations.[27] Several mechanisms have been
reported to explain why synonymous mutations are related to the
changes in phenotype.[27] In the precursor mRNAs of human
genes, exons are separated by noncoding introns. The spliceo-
some regulates and executes the removal of introns by targeting
the correct exon-intron boundary. AG dinucleotides are
conserved at the intron ends. The 2 synonymous mutations
detected in this study are both resulted in AG sequence, which
may provide alternative splicing and affect splicing accuracy of
the genes. However, we do know that more experiments need to
be performed to illustrate the pathogenic mechanisms.
People with the same variant may represent different
phenotypes. In this study, we detected c.538C>T (GJB3) and
c.1464+2T>A (ESPN) in proband HL11. Mutations in gene
GJB3 and ESPN both have been described as causative of HL.
These variants were also conﬁrmed in the proband father using
[3] Kennedy CR, McCann DC, Campbell MJ, et al. Language ability after
Sun et al. Medicine (2019) 98:12 www.md-journal.comSanger sequencing. However, the proband father shows no
syndrome at all. These results showed the high heterogeneity of
heredity HL.
In this study, we perform BGISEQ-500 PE50 sequencing in the
detection of disease-causing mutations in HL patients in real
clinical setting. When we discuss the possibility of using a new
method in real clinical setting, cost, turnaround time and
throughput should be evaluated ﬁrst. BGISEQ platform can
greatly reduce the cost of sequencing. Turnaround time is the key
point for the application of NGS technology in clinical practice.
The entire workﬂow of this method lasts approximately 8 days
from the recruitment of sample to clinical reporting. The whole
testing workﬂow includes DNA extraction (0.5 day), library
construction (1.5 day), DNBs making and loading (0.5 day),
sequencing using BGISEQ-500 (3.5 day), bioinformatics analysis,
annotation, and reporting (2 day) for 1 sample.
In summary, we developed a targeted NGS method for
proﬁling of clinically disease-causing mutations in patients with
HL. We performed this method in 58 clinical cases and found
disease-causing mutations in 45 patients. The results proved that
targeted NGS technology using BGISEQ-500 platform could be
used for clinical genetic testing in patients with HL.Acknowledgments
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